title: [A case of massive pancreatic neuroendocrine carcinoma successfully treated with surgical resection and postoperative everolimus administration].
abstract: A 55-year-old woman presented to our hospital with a chief complaint of abdominal pain. Computed tomography (CT) revealed a massive tumor originating from the tail of the pancreas, with liver and lymph node metastasis. Percutaneous biopsy was performed and yielded a diagnosis of pancreatic neuroendocrine carcinoma. The patient underwent distal pancreatectomy, lateral segmentectomy of the liver, para-aortic lymph node dissection, and cytoreductive surgery for treatment of peritoneal dissemination. Octreotide was administered on post-operative day (POD) 3. Treatment with everolimus (10 mg/day) was initiated on POD 32. Stable disease according to the Response Evaluation Criteria in Solid Tumors( RECIST) was observed for 4 months, and the patient survived for a total of 9 months after surgery. Everolimus was tolerated safely and was effective for the treatment of pancreatic neuroendocrine carcinoma.
authors.affiliation: Dept. of Surgery, Kansai Rosai Hospital.
authors.forename: Yosuke
authors.initials: Y
authors.lastname: Mukai
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Takeda
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Yoshiteru
authors.initials: Y
authors.lastname: Katsura
authors.forename: Hiroki
authors.initials: H
authors.lastname: Kusama
authors.forename: Naoyoshi
authors.initials: N
authors.lastname: Hashimoto
authors.forename: Katsunori
authors.initials: K
authors.lastname: Matsushita
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kawashima
authors.forename: Michiko
authors.initials: M
authors.lastname: Hamanaka
authors.forename: Yoshinori
authors.initials: Y
authors.lastname: Kagawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Takeno
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Okishiro
authors.forename: Hideki
authors.initials: H
authors.lastname: Sakisaka
authors.forename: Rei
authors.initials: R
authors.lastname: Suzuki
authors.forename: Chiyomi
authors.initials: C
authors.lastname: Egawa
authors.forename: Hirokazu
authors.initials: H
authors.lastname: Taniguchi
authors.forename: Takeshi
authors.initials: T
authors.lastname: Kato
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D000068338:Everolimus; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D010166:Palliative Care; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus; D020123:Sirolimus